Armour Thyroid vs Tirosint: Long-Term Durability of Response

What Makes These Two Drugs Different at a Pharmacological Level

Armour Thyroid and Tirosint differ at a fundamental level that has real consequences for how stable thyroid hormone levels remain over months and years. Armour Thyroid is a desiccated porcine thyroid extract containing both thyroxine (T4) and triiodothyronine (T3) in a fixed 4:1 ratio by weight. Tirosint is a soft-gel capsule containing only synthetic levothyroxine (T4) dissolved in gelatin, glycerin, and water, with no cellulose fillers, acacia, or dyes.

The T3 Variable in Armour Thyroid

The T3 content in Armour Thyroid is the single biggest factor shaping its long-term durability profile. Porcine thyroid glands contain T3 at a concentration roughly four times higher than the human thyroid produces relative to T4. That means a patient taking one grain (60 mg) of Armour Thyroid receives approximately 9 mcg of T3 per dose, a bolus that peaks in serum within 2 to 4 hours and dissipates quickly given T3's 1-day half-life [1]. Over time, this creates a cycle of T3 peaks and troughs that complicates TSH interpretation and may require more frequent dose adjustments.

How Tirosint Bypasses the Absorption Problem

Standard levothyroxine tablets require dissolution in gastric acid, and absorption can fall 20 to 40% when patients take calcium, iron, proton pump inhibitors, or coffee within an hour of the dose [2]. Tirosint's gel-capsule matrix dissolves rapidly and delivers levothyroxine directly without those filler-related interactions. That absorption consistency is the core mechanism behind its durability advantage: when the amount absorbed is predictable, the steady-state TSH is predictable.

Long-Term TSH Stability: What the Trial Data Actually Show

TSH stability over one to three years is the most clinically meaningful proxy for durability of response. The data favor Tirosint-class levothyroxine formulations for maintaining target TSH, though the evidence base for head-to-head comparisons beyond six months remains thin.

The Hoang 2013 Crossover Trial

Hoang et al. Conducted a randomized, double-blind, crossover trial (N=70) comparing desiccated thyroid extract (DTE) to levothyroxine over two 16-week treatment periods [1]. Patients' TSH levels were kept within a target range during both phases. The trial found no statistically significant difference in quality of life (measured by thyroid symptom questionnaires and SF-36), and body weight favored DTE by a mean of 1.8 kg (P<0.001). However, free T3 levels were meaningfully higher in the DTE arm, and free T4 levels were lower. The trial design did not extend beyond 16 weeks per arm, so it cannot speak to TSH drift over multiple years.

The Vita 2014 Cohort

Vita et al. Studied 46 hypothyroid patients with documented malabsorption conditions and compared TSH normalization rates on Tirosint versus standard levothyroxine tablets [3]. Tirosint normalized TSH in 88.5% of patients compared with a substantially lower rate for conventional tablets. The authors concluded that the liquid or gel-cap formulation "should be considered the first-line treatment in hypothyroid patients with conditions interfering with levothyroxine absorption." This finding is directly relevant to durability because any formulation that produces inconsistent absorption will generate dose-creep and TSH oscillation over time.

Real-World Evidence on Armour Thyroid TSH Variability

Published observational data suggest that patients on desiccated thyroid extract have wider TSH fluctuations than matched patients on levothyroxine monotherapy. A 2017 analysis in the Journal of Clinical Endocrinology and Metabolism found that DTE-treated patients were more likely to have suppressed TSH values (<0.1 mIU/L) during follow-up, raising questions about subclinical hyperthyroidism risk over years [4]. Sustained TSH suppression correlates with atrial fibrillation risk (hazard ratio approximately 1.44 in older adults) and accelerated bone loss, particularly in postmenopausal women [5].

The HealthRX clinical team uses the following durability-assessment framework when reviewing a patient's thyroid therapy at the 12-month mark:

1. Obtain a fasting TSH, free T4, and free T3 drawn consistently at the same time of day, at least 4 hours after the morning dose.
2. Flag any patient whose TSH has varied by more than 1.0 mIU/L across three consecutive readings without a dose change. That variability pattern is the earliest signal of formulation-related instability.
3. If the patient is on Armour Thyroid and shows TSH suppression alongside a free T3 above 4.2 pg/mL, reduce the grain count before assuming the dose is "wrong."
4. If the patient is on standard levothyroxine tablets and shows persistently high TSH despite adherence, consider a trial of Tirosint before increasing dose.

Symptom Durability: Do Patients Feel Better Longer on One vs the Other?

Symptom durability is harder to measure than TSH and is driven partly by the degree to which free T3 is maintained in the upper half of the reference range throughout the day.

Patient-Reported Outcomes in Published Trials

The Hoang 2013 crossover trial used the General Health Questionnaire (GHQ), thyroid symptom score, and SF-36 and found no significant difference in overall quality of life between DTE and levothyroxine at 16 weeks [1]. A subset of patients (48.6%) did express a preference for DTE at the end of the study, however, citing improved energy and cognitive function. That preference signal is real but falls short of statistical significance on validated endpoints.

A 2019 patient survey published in Thyroid (N=12,146) found that patients on DTE or combination T4/T3 therapy rated their overall well-being higher than patients on levothyroxine monotherapy [6]. Survey data carry obvious confounders, but a pattern this consistent across a large population cannot be dismissed.

Why T3 Content Matters for Sustained Symptom Relief

Roughly 10 to 15% of patients with hypothyroidism may carry polymorphisms in the deiodinase 2 gene (DIO2) that reduce peripheral conversion of T4 to T3 [7]. For those patients, a T4-only preparation like Tirosint may leave free T3 chronically low even when TSH is normal, and symptoms persist. Armour Thyroid's T3 component provides direct T3 regardless of DIO2 status. The practical implication: symptom durability on Tirosint depends on intact T4-to-T3 conversion, while symptom durability on Armour Thyroid depends on tolerating the T3 peaks without cardiovascular or anxiety side effects.

The Bone and Cardiac Durability Question

Long-term DTE use at doses that suppress TSH below 0.5 mIU/L carries a documented bone mineral density risk. A meta-analysis of 41 cohort studies found that suppressive thyroid hormone therapy was associated with a standardized mean difference of 0.71 in bone loss at the femoral neck in postmenopausal women [5]. Tirosint, when dosed to keep TSH within the normal range, does not carry that signal. This distinction makes Tirosint the more favorable option for women over 50 who prioritize long-term skeletal health.

Absorption, Formulation Stability, and Why They Affect Long-Term Outcomes

A drug's long-term durability is only as good as its delivery consistency. Both Armour Thyroid and Tirosint have absorption profiles that differ from standard levothyroxine tablets, but in different ways and with different implications.

Armour Thyroid Lot-to-Lot Variability

Armour Thyroid is a natural product derived from porcine thyroid glands. The United States Pharmacopeia (USP) sets a permissible range of 90 to 110% of labeled potency for T4 content and a range of 85 to 115% for T3 in desiccated thyroid preparations. T3's potency variability combined with its short half-life means that a patient stabilized on one manufacturing lot may experience symptoms or TSH changes when the pharmacy dispenses a new lot. This is not a theoretical concern. The FDA has received multiple voluntary recalls for desiccated thyroid products related to potency deviations [8].

Tirosint's Formulation Advantage

Because Tirosint contains only levothyroxine, gelatin, glycerin, and water, it eliminates the most common causes of tablet levothyroxine absorption variability: acacia binders, lactose fillers, and talc. The bioavailability of Tirosint is approximately 81 to 86%, compared to roughly 60 to 80% for conventional tablets in real-world conditions [2]. That higher and more stable floor is the primary reason endocrinologists cite when recommending Tirosint for patients who cannot achieve stable TSH on tablets.

Drug Interactions That Affect Durability

Both preparations interact with the same broad category of drugs: calcium carbonate, ferrous sulfate, bile acid sequestrants, proton pump inhibitors, and antacids reduce levothyroxine absorption. Armour Thyroid's T3 component adds a separate interaction concern because T3 is more quickly absorbed and more susceptible to interference from medications that accelerate gastric emptying or alter enterohepatic circulation. Patients taking rifampin, phenytoin, or carbamazepine may see faster T3 clearance, requiring more frequent Armour Thyroid dose adjustments than they would face on Tirosint.

Switching Protocols: Moving From Armour Thyroid to Tirosint (and Back)

Switching between these two drugs requires careful attention to dose equivalency and a monitoring plan that accounts for the different pharmacokinetics.

Converting Armour Thyroid to Tirosint

The generally accepted conversion ratio is 1 grain (60 mg) of Armour Thyroid to approximately 100 mcg of levothyroxine equivalent, though some patients require 88 mcg or 112 mcg depending on TSH response [9]. When switching to Tirosint specifically, clinicians should use the lower end of the equivalent range initially (88 mcg per grain) because Tirosint's higher bioavailability means a given mcg dose delivers more T4 than a standard tablet at the same labeled dose.

Practical protocol used by many endocrinologists:

• Stop Armour Thyroid on day 1.
• Start Tirosint at 85 to 90% of the calculated levothyroxine equivalent.
• Recheck TSH and free T4 at 6 weeks, not 8 to 12 weeks, because patients switching from DTE often have low free T4 at baseline despite a suppressed TSH and need a faster assessment window.
• Adjust by 12 to 13 mcg increments (one half-tablet equivalent) until TSH stabilizes within target.

Converting Tirosint to Armour Thyroid

This direction is less common but requested by patients with persistent symptoms on T4-only therapy. The conversion starts at 60 mg of Armour Thyroid per 100 mcg of Tirosint and goes down to 45 to 50 mg per 100 mcg for patients who are sensitive to T3 effects. Free T3 should be checked 4 to 6 hours post-dose at the 6-week mark to ensure the T3 peak is not excessive. TSH alone is insufficient here because the T3 bolus from Armour can suppress TSH at a dose that leaves the patient hypothyroid 18 hours later.

Who Should Not Switch to Armour Thyroid

Patients with a history of atrial fibrillation, osteoporosis with a T-score below -2.5, or adrenal insufficiency should not switch to Armour Thyroid without careful specialist review. The American Thyroid Association's 2014 guidelines note that "evidence-based recommendations cannot be made for or against DTE use" but specifically flag cardiovascular and bone risk as factors requiring individualized assessment [9].

Which Patients Do Best on Each Drug Long-Term

Long-Term Candidates for Tirosint

• Patients with celiac disease, inflammatory bowel disease, or post-bariatric anatomy who cannot reliably absorb tablet formulations.
• Patients on multiple medications with high interaction risk.
• Patients over 65 where TSH suppression risk outweighs any symptom benefit.
• Patients who achieved TSH control on standard levothyroxine but lose it with each brand change or generic switch (Tirosint's single-formulation manufacturing reduces that problem).
• Pregnant women where stable thyroid hormone levels are critical for fetal development and TSH targets shift by trimester.

Long-Term Candidates for Armour Thyroid

• Patients with persistent fatigue, brain fog, and weight gain despite a consistently normal TSH and free T4 on T4-only therapy.
• Patients with confirmed low free T3 in the lower quartile of the reference range (<2.3 pg/mL) while on an adequate levothyroxine dose.
• Patients who trialed combination synthetic T4/T3 (levothyroxine plus liothyronine) and preferred it but want a single pill.
• Younger patients without cardiovascular risk factors where TSH suppression is easier to monitor and manage.

The 2013 Hoang trial's finding that 48.6% of patients preferred DTE suggests a real and persistent subset of patients for whom Armour Thyroid is the better long-term fit [1]. Dismissing that preference without investigating free T3 status and DIO2 polymorphism likelihood is a clinical shortcut that leaves patients undertreated.

Practical Monitoring Schedule for Long-Term Durability

Regardless of which drug a patient uses, the monitoring schedule determines whether durability is maintained.

For Tirosint: TSH and free T4 every 6 to 12 months once stable. Annual review of any new medications, supplements, or GI conditions that could shift absorption. Bone mineral density scan every 2 years if TSH is kept at or below 0.5 mIU/L.

For Armour Thyroid: TSH, free T4, and free T3 every 3 to 6 months. Post-dose T3 check (4 hours after the morning grain) at least annually to confirm the T3 peak remains below 4.5 pg/mL. Resting heart rate and blood pressure at each visit. DEXA scan every 2 years for postmenopausal women.

The American Association of Clinical Endocrinology (AACE) position statement on hypothyroidism management recommends that any patient on thyroid replacement therapy have TSH measured within 4 to 8 weeks of any dose change and at least annually once stable [10].